Psych · Emergency psychiatry
Neuroleptic malignant syndrome
Also known as NMS · Neuroleptic malignant syndrome · Antipsychotic malignant syndrome · Malignant neuroleptic syndrome · Drug-induced hyperthermic rigidity syndrome
Exam-exhaustive fellowship topic on neuroleptic malignant syndrome — Gurrera international consensus diagnostic criteria with critical values, differentials (serotonin toxicity, malignant catatonia, heat stroke, malignant hyperthermia), CK and labs, stop dopamine antagonists, supportive/ICU care, bromocriptine/dantrolene/ECT debates, atypical SGA presentations, and delayed careful antipsychotic rechallenge. FRANZCP-primary, globally tagged.
On this page
Study tools
Your progress
Saved on this device.
Target exams
Red flags
- Fever plus lead-pipe rigidity after dopamine antagonist exposure — stop all antipsychotics immediately and escalate medically
- Rising CK with autonomic instability — rhabdomyolysis and AKI risk; treat as medical emergency not primary psychiatric agitation
- Giving more antipsychotic for 'agitation' during evolving NMS — life-threatening error
- Hyperreflexia and clonus with serotonergic drugs — serotonin toxicity pathway, not NMS
- Refractory rigidity-hyperthermia or malignant catatonia overlap — consider ECT early with critical-care support
- Premature antipsychotic rechallenge before full resolution — high recurrence risk
- Clozapine or SGA 'atypical NMS' without classic rigidity — do not wait for textbook tetrad
Meet the patient
A 34-year-old man, three days into a haloperidol escalation for a first psychotic episode, is found mute and drenched in sweat on the ward. His arm will not bend when the nurse tries to take bloods — it feels like a lead pipe. Temperature 39.1, HR 132, BP swinging 95/52 to 172/104, and the laboratory rings through with a CK at about twenty times the upper limit of normal.[3][6][16]
The registrar's first instinct is to label the restlessness "agitation" and give another PRN antipsychotic. The examiner's question is the one that decides whether this patient lives: is this NMS, what do you do in the next ten minutes, and what will you absolutely not give? This topic is the disciplined answer — and the first word of that answer is stop.[3][8][22]
References22ShowHide
- [1]Gurrera RJ, Caroff SN, Cohen A, et al. An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method J Clin Psychiatry, 2011.PMID 21733489
- [2]Gurrera RJ, Mortillaro G, Velamoor V, et al. A Validation Study of the International Consensus Diagnostic Criteria for Neuroleptic Malignant Syndrome J Clin Psychopharmacol, 2017.PMID 28027111
- [3]Strawn JR, Keck PE Jr, Caroff SN Neuroleptic malignant syndrome Am J Psychiatry, 2007.PMID 17541044
- [4]Caroff SN, Mann SC Neuroleptic malignant syndrome Med Clin North Am, 1993.PMID 8093494
- [5]Levenson JL Neuroleptic malignant syndrome Am J Psychiatry, 1985.PMID 2863986
- [6]Berman BD Neuroleptic malignant syndrome: a review for neurohospitalists Neurohospitalist, 2011.PMID 23983836
- [7]Tse L, Barr AM, Scarapicchia V, et al. Neuroleptic Malignant Syndrome: A Review from a Clinically Oriented Perspective Curr Neuropharmacol, 2015.PMID 26411967
- [8]Pileggi DJ, Cook AM Neuroleptic Malignant Syndrome Ann Pharmacother, 2016.PMID 27423483
- [9]Wijdicks EFM, Ropper AH Neuroleptic Malignant Syndrome N Engl J Med, 2024.PMID 39321364
- [10]Modi S, Dharaiya D, Schultz L, et al. Neuroleptic Malignant Syndrome: Complications, Outcomes, and Mortality Neurocrit Care, 2016.PMID 26223336
- [11]Kuhlwilm L, Schönfeldt-Lecuona C, Gahr M, et al. The neuroleptic malignant syndrome-a systematic case series analysis focusing on therapy regimes and outcome Acta Psychiatr Scand, 2020.PMID 32659853
- [12]Belvederi Murri M, Guaglianone A, Bugliani M, et al. Second-generation antipsychotics and neuroleptic malignant syndrome: systematic review and case report analysis Drugs R D, 2015.PMID 25578944
- [13]Ananth J, Parameswaran S, Gunatilake S, et al. Neuroleptic malignant syndrome and atypical antipsychotic drugs J Clin Psychiatry, 2004.PMID 15119907
- [14]Lally J, McCaffrey C, OʼMurchu C, et al. Clozapine Rechallenge Following Neuroleptic Malignant Syndrome: A Systematic Review J Clin Psychopharmacol, 2019.PMID 31205196
- [15]Rosebush PI, Stewart TD, Gelenberg AJ Twenty neuroleptic rechallenges after neuroleptic malignant syndrome in 15 patients J Clin Psychiatry, 1989.PMID 2569457
- [16]Velamoor VR, Norman RM, Caroff SN, et al. Progression of symptoms in neuroleptic malignant syndrome J Nerv Ment Dis, 1994.PMID 7906709
- [17]Perry PJ, Wilborn CA Serotonin syndrome vs neuroleptic malignant syndrome: a contrast of causes, diagnoses, and management Ann Clin Psychiatry, 2012.PMID 22563571
- [18]Dunkley EJ, Isbister GK, Sibbritt D, et al. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity QJM, 2003.PMID 12925718
- [19]Boyer EW, Shannon M The serotonin syndrome N Engl J Med, 2005.PMID 15784664
- [20]Rogers JP, Oldham MA, Fricchione G, et al. Evidence-based consensus guidelines for the management of catatonia: Recommendations from the British Association for Psychopharmacology J Psychopharmacol, 2023.PMID 37039129
- [21]Connell J, Oldham M, Pandharipande P, et al. Malignant Catatonia: A Review for the Intensivist J Intensive Care Med, 2023.PMID 35861966
- [22]Gurrera RJ Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome Am J Psychiatry, 1999.PMID 9989551